In addition to activating TGF, lowering intraglomerular pressure and lowering hyperfiltration-mediated kidney damage, SGLT2 inhibitors promote multiple other favorable physiologic pathways that contribute to kidney health. This evidence concerns the gene SLC5A2 and Nephropathy.